FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Broadrick Dale 2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [ BRTX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)
3003 BRICK CHURCH PIKE		 3. Date of Earliest Transaction (MM/DD/YYYY)
6/3/2022
(Street)
NASHVILLE, TN 37207
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  6/3/2022    P    1200  A $4.8994 (1) 279673  D   
Common Stock  6/6/2022    P    3000  A $4.9325 (2) 282673  D   
Common Stock                 316972  I (3) See footnote 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to acquire Common Stock  $120                  2/19/2019  2/19/2024  Common Stock  125    125  D   
Warrant to acquire Common Stock  $120                  2/19/2019  2/19/2024  Common Stock  125    125  D   
Warrant to acquire Common Stock  $120                  5/7/2019  5/7/2024  Common Stock  138    138  D   
Warrant to acquire Common Stock  $120                  5/7/2019  5/7/2024  Common Stock  138    138  D   
Warrant to acquire Common Stock  $120                  10/16/2019  10/16/2024  Common Stock  833    833  D   

Explanation of Responses:
(1)  This transaction was executed in multiple trades at prices ranging from $4.80 to $4.9199 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
(2)  This transaction was executed in multiple trades at prices ranging from $4.8531 to $4.9676 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
(3)  Owned by Fleetco, Inc. of which reporting person is a 93% shareholder.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Broadrick Dale
3003 BRICK CHURCH PIKE
NASHVILLE, TN 37207
X


Signatures
/s/ Dale Broadrick 6/7/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more BioRestorative Therapies Charts.
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more BioRestorative Therapies Charts.